GSK Appeals Against NICE Decision To Deny Women Advanced Breast Cancer Treatment, Tyv
 

GlaxoSmithKline (GSK) confirmed that it is to appeal against the decision by NICE to deny NHS funding for Tyverb® (lapatinib), a treatment for an aggressive form of advanced breast cancer (ErbB2-positive).1 If successful the appeal will enable the NHS to offer a similar level of access to lapatinib as other EU countries.

More...

This is good news, I guess, but it is quite disturbing to read acknowledgements that yes, this is effective but it's not worth the money. I think I'm worth it.

Glad we did the petition and got support from our sisters on the board. I think i'm worth it to! Shame on the British government who recklessly spend taxpayers money on wars and bankers but deny it's citizens life prolonging medication.